MUC16 and neoplasm: In contrast to earlier toxicity concerns of utilizing aggregated TRAIL preparations for clinical applications, Meso-TR3 would only form higher order clusters at the tumor cell membrane following interaction with multiple binding sites on MUC16, which then converts the soluble drug into a highly potent membrane anchored tumor cell killer.